Reduction in Overall Occurrences of Ischemic Events With Vorapaxar: Results From TRACER

BACKGROUND: Clinical trials traditionally use time‐to‐first‐event analysis embedded within the composite endpoint of cardiovascular death (CVD), myocardial infarction (MI), or stroke. However, many patients have >1 event, and this approach may not reflect overall experience. We addressed this by...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Am Heart Assoc
Auteurs principaux: White, Harvey D., Huang, Zhen, Tricoci, Pierluigi, Van de Werf, Frans, Wallentin, Lars, Lokhnygina, Yuliya, Moliterno, David J., Aylward, Philip E., Mahaffey, Kenneth W., Armstrong, Paul W.
Format: Artigo
Langue:Inglês
Publié: Blackwell Publishing Ltd 2014
Sujets:
Original Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4310394/
https://ncbi.nlm.nih.gov/pubmed/25012288
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.114.001032
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires